查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1985733

神经性贪食症市场：依治疗类型、治疗环境、通路和最终用户划分－2026-2032年全球市场预测

Binge Eating Disorder Market by Treatment Type, Treatment Setting, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，神经性贪食症市场价值将达到 6.2343 亿美元，到 2026 年将成长至 6.648 亿美元，到 2032 年将达到 9.5157 亿美元，复合年增长率为 6.22%。

主要市场统计数据
基准年 2025 6.2343亿美元
预计年份：2026年 6.648亿美元
预测年份 2032 9.5157亿美元
复合年增长率 (%) 6.22%

全面介绍神经性贪食症的临床、社会和经济层面，以及采取全面照护方法的必要性。

神经性贪食症（BED）是一种具有临床意义的饮食障碍，其特征是反覆出现大量进食和丧失自控能力的情况。除了诊断标准之外，这种疾病还会产生多方面的临床、心理和社会影响，影响所有年龄层和所有医疗机构的患者。 BED 患者通常伴随情绪障碍、焦虑障碍、代谢併发症和功能障碍，因此需要采用协作式的多学科治疗方法来解决这些问题。

神经性贪食症治疗生态系统正在发生变革性的变化，涵盖整个护理过程，包括重塑临床路径、引入数位技术以及提高患者参与度。

在技​​术进步、临床创新和保险公司不断变化的期望的推动下，神经性贪食症的治疗格局正在经历一场变革。数位疗法和远端医疗平台正在加速患者获得实证心理治疗和自我管理工具，从而实现「阶梯式照护」模式，使患者能够根据需要从基层医疗逐步过渡到专科干预。同时，人们对药物治疗和辅助性治疗的兴趣日益浓厚，促使人们重新评估整体治疗策略，这些策略旨在支持患者参与心理治疗，并利用药物治疗来减轻症状严重程度。

评估 2025 年美国关税变化对治疗供应链和跨境临床合作的累积影响。

影响关税的政策措施可能会对整个医疗保健生态系统产生累积效应，尤其会影响到支持药品、医疗设备以及用于治疗神经性贪食症的数位平台的供应链。提高进口药品和医疗设备的关税可能导致医疗服务提供者和保险公司的成本上升，促使供应链管理者调整筹资策略、增加库存或加速将製造地迁至更靠近终端市场的位置。这些供应方的因应措施反过来又会影响医院、专科医疗中心和分销合作伙伴之间的采购週期和合约谈判。

透过细分洞察治疗类型、分销管道、最终用户人口统计特征和治疗环境如何影响临床路径和医疗保健服务。

了解神经性贪食症的治疗模式需要对治疗方法、分销管道、最终用户和治疗环境等方面的细分市场进行详细分析。根据治疗类型，市场可分为数位疗法、药物疗法和心理疗法，并进行相应研究。数位疗法又可细分为行动应用和网页版两种模式；药物疗法可细分为抗忧郁症、抗惊厥药和兴奋剂；心理疗法可细分为认知行为疗法、辩证行为疗法和人际关係疗法。每个细分市场都有其独特的监管、临床疗效检验和商业化要求。数位疗法需要证明其在数位终端上的使用者参与度和临床疗效；药物疗法需要经过安全性和标籤核准流程；而心理疗法则需要对从业人员进行培训并监测治疗依从性，才能有效扩大规模。

区域性见解比较盛行率、医疗保健基础设施、报销和创新采纳——这些因素会影响获得治疗和服务的机会。

区域趋势对神经性贪食症的辨识、治疗和报销有显着影响，进而塑造临床计画和产业计画的策略重点。在美洲，医疗专业人员意识的提高和远端医疗正在推动整合式医疗模式的广泛应用，但公共和私人保险公司政策的区域差异意味着报销和就医途径在不同地区存在显着差异。因此，需要与保险公司和医疗系统进行本地合作，透过结果和成本抵销分析来证明其价值。

从企业层面深入了解治疗和数位治疗提供者的策略定位、合作伙伴关係、研究重点和差异化。

神经性贪食症领域的企业策略由临床创新、策略伙伴关係和目标明确的商业化模式共同构成。领先的临床开发公司和数位疗法提供者正致力于进行严格的疗效评估，并透过随机对照试验和真实世界数据来验证疗效，从而推动与支付方的对话。同时，技术提供者与成熟的行为健康网络之间的合作，正在推动试点计画将数位工具整合到现有的诊疗路径中，从而降低临床医生采用和患者入院的障碍。

为领导者提供切实可行的建议，以加快实施速度，加强护理路径，并调整策略以适应不断变化的临床和监管环境。

业界领导者应推动一系列切实可行的倡议，在保障商业性可行性的同时，加速实证医疗服务的普及。首先，应优先发展整合式医疗模式，将心理治疗介入与药物治疗和数位疗法结合，并投资于长期疗效评估，以证明其临床和经济价值。其次，应开发互通性和便于临床医师使用的工作流程，使数位疗法无缝融入日常诊疗，进而降低应用门槛，提高病患依从性。

高度透明的调查方法，明确规定了资料来源、分析框架、检验程序和品管，以确保严谨且可重复的见解。

本报告采用主导调查方法，基于多资讯来源，旨在最大限度地提高可靠性和透明度。主要资料来源包括同侪审查的临床文献、註册登记和临床试验资料库、监管文件，以及对临床医生、保险公司、数位医疗创新者和供应链专家的定性访谈。这些资讯来源经过交叉检验，以校正研究设计、患者族群和结果指标的差异，并评估临床效果在不同背景下的稳健性。

一份权威的综合分析报告，重点阐述了战略重点、综合护理的紧迫性，并为临床和政策领域的相关人员指明了未来行动的明确方向。

神经性贪食症的现状既充满机会也面临挑战。数位疗法的进步、药物研究的重新运作以及不断演进的照护模式正在为改善治疗的可及性和疗效开闢道路，但要充分发挥这些潜力，需要临床、商业和政策相关人员的通力合作。整合心理治疗、药物治疗和数位支援的综合护理路径对于实现持久疗效和减少復发至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法分類的暴食症饮食失调市场

  • 数位疗法
    • 行动应用
    • 基于网路的
  • 药物治疗
    • 抗忧郁症
    • 抗癫痫药物
    • 兴奋剂
  • 心理治疗
    • 认知行为疗法
    • 辩证行为疗法
    • 人际关係疗法

第九章：依治疗环境分類的贪食症饮食失调市场

  • 住院治疗
  • 门诊

第十章：暴食症饮食失调市场：依通路划分

  • 家庭医疗保健
  • 医院和诊所
  • 线上平台
  • 专业治疗中心

第十一章：暴食症饮食失调市场：依最终用户划分

  • 青年
  • 成人
  • 老年人

第十二章：暴食症饮食失调市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：暴食症饮食失调市场：依群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：暴食症饮食失调市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国暴食症市场

第十六章：中国暴食症市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alsana, Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc. by SK Capital Partners LLP
  • BALANCE Eating Disorder Treatment Center
  • Carolina House Eating Disorder Treatment Center
  • Center for Change
  • Equip Health, Inc.
  • Hikma Pharmaceuticals PLC
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Innovative Medicine by Johnson and Johnson
  • Monte Nido & Affiliates Holdings, LLC
  • Montecatini Eating Disorder Treatment Center
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Red Oak Recovery
  • Rhodes Pharmaceuticals LP by Purdue Pharma LP
  • SimSon Pharma Limited
  • Sunovion Pharmaceuticals Inc. by Sumitomo Pharma
  • Takeda Pharmaceutical Company Limited
  • TalktoAngel
  • The London Centre for Eating Disorders and Body Image Ltd.
  • TheraCryf Plc
  • Timberline Knolls Residential Treatment Center
  • Viatris Inc.
Product Code: MRR-757B1C9CB0B3

The Binge Eating Disorder Market was valued at USD 623.43 million in 2025 and is projected to grow to USD 664.80 million in 2026, with a CAGR of 6.22%, reaching USD 951.57 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 623.43 million
Estimated Year [2026] USD 664.80 million
Forecast Year [2032] USD 951.57 million
CAGR (%) 6.22%

Comprehensive introduction outlining the clinical, social, and economic dimensions of binge eating disorder and the imperative for integrated care approaches

Binge eating disorder (BED) is a clinically significant eating disorder characterized by recurrent episodes of consuming large amounts of food accompanied by a perceived loss of control. Beyond diagnostic criteria, the condition carries multifaceted clinical, psychological, and social consequences that affect individuals across age groups and care settings. Individuals living with BED often experience comorbid mood and anxiety disorders, metabolic complications, and functional impairment that together require coordinated, multidisciplinary approaches to care.

Recent shifts in care delivery and technology integration have increased awareness among clinicians and payers, yet gaps remain in timely diagnosis, access to evidence-based therapies, and continuity of care after acute intervention. In addition, stigma and underreporting contribute to delayed treatment seeking, particularly among underserved populations. Consequently, clinical leaders and health system administrators are focused on closing care gaps through diagnostic screening in primary care, integration of behavioral health into medical settings, and expanded training on evidence-based psychotherapies.

Given these dynamics, a strategic introduction to the landscape centers on the need for integrated care pathways that combine behavioral interventions, pharmacologic options where clinically appropriate, and digital therapeutics to extend reach. This introduction frames the priorities that follow: optimizing patient identification, aligning care modalities across settings, and ensuring that commercial and policy decisions support durable, equitable access to effective treatment.

Transformative shifts reshaping clinical pathways, digital adoption, and patient engagement in binge eating disorder treatment ecosystems across care continuums

The treatment landscape for binge eating disorder is undergoing transformative shifts driven by technology, clinical innovation, and evolving payer expectations. Digital therapeutics and telehealth platforms have accelerated patient access to evidence-based psychotherapies and self-management tools, enabling stepped-care approaches that begin in primary care and escalate to specialist intervention when needed. Concurrently, renewed interest in pharmacologic agents and adjunctive treatments has prompted a re-examination of combined-modality strategies where medication is used to support engagement in psychotherapy and reduce symptom severity.

Regulatory frameworks and reimbursement models are responding to these changes, with value-based contracting and outcomes-based reimbursement gaining traction in pockets where measurable clinical outcomes can be demonstrated. These dynamics incentivize developers to prioritize real-world evidence generation and validated outcome measures. At the same time, partnerships between digital health innovators, specialty treatment centers, and payers are becoming more common, reflecting a recognition that no single stakeholder can address access, quality, and affordability alone.

As a result, stakeholders must adapt to an ecosystem where patient engagement platforms, clinical decision support tools, and multidisciplinary care teams intersect. Investment in interoperability, clinician training on digital modalities, and robust data governance are necessary to convert technological promise into improved clinical outcomes. Looking forward, integration of behavioral analytics and precision approaches to treatment selection will further reshape care pathways and help personalize interventions for better long-term recovery.

Assessment of cumulative impacts from United States tariff changes in twenty twenty five on therapeutic supply chains and cross-border clinical collaborations

Policy actions affecting tariffs can have a cumulative impact on the broader healthcare ecosystem and specifically on the supply chains that underpin therapeutics, devices, and digital platforms used in binge eating disorder care. Increases in duties on imported pharmaceuticals or medical devices may raise costs for providers and payers, prompting supply chain managers to adjust sourcing strategies, build larger inventories, or accelerate relocation of manufacturing closer to end markets. These supply-side responses, in turn, influence procurement cycles and contract negotiations across hospitals, specialty centers, and distribution partners.

For digital health providers and platform vendors, indirect impacts can also emerge when hardware components, sensors, or ancillary devices are subject to tariff changes. Higher input costs can necessitate price adjustments or altered product roadmaps, while longer lead times for components can slow device-based pilots or rollouts. Clinical trial logistics and international collaboration on research may face friction if cross-border exchanges of equipment or study materials become more costly or administratively burdensome.

Strategic responses to tariff-driven disruption tend to center on diversification and resilience. Organizations are increasingly pursuing nearshoring, dual-sourcing, and advanced inventory management to reduce exposure to single-country policy shocks. They are also engaging earlier with supply chain and procurement teams when designing clinical programs to account for potential cost and timing variability. Moreover, meaningful contingency planning and transparent communication with payers and provider partners enable smoother transitions and protect patient continuity of care during periods of regulatory and trade uncertainty.

Segmentation insights on how treatment type, distribution channel, end-user demographics, and treatment setting influence clinical pathways and care delivery

Understanding how care is delivered for binge eating disorder requires a granular look at segmentation across treatment modality, distribution, end users, and care setting. Based on Treatment Type, the market is studied across Digital Therapeutics, Pharmacotherapy, and Psychotherapy, with Digital Therapeutics further studied across Mobile App and Web Based delivery models, Pharmacotherapy further studied across Antidepressants, Antiepileptics, and Stimulants, and Psychotherapy further studied across Cognitive Behavioral Therapy, Dialectical Behavior Therapy, and Interpersonal Psychotherapy. These subsegments each present unique regulatory, clinical validation, and commercialization requirements: digital therapeutics must demonstrate engagement and clinical effect across digital endpoints, pharmacotherapies must navigate safety and labeling pathways, and psychotherapeutic modalities require workforce training and fidelity monitoring to scale effectively.

In parallel, distribution channels frame access points for care. Based on Distribution Channel, the market is studied across Home Healthcare, Hospitals And Clinics, Online Platforms, and Specialty Treatment Centers, each of which imposes distinct operational needs around clinician workflows, reimbursement codes, and integration with electronic health records. Home healthcare and online platforms expand reach into patient daily environments but require robust remote monitoring and privacy safeguards. Hospitals and clinics provide diagnostic capacity and acute management, while specialty treatment centers concentrate expertise for complex or refractory cases.

Patient populations shape demand and design of services. Based on End User, the market is studied across Adolescents, Adults, and Elderly populations, and differentiation by age group influences clinical features, comorbidity profiles, and engagement preferences. Adolescents may access school-based screening and family-centered interventions, adults often require integrated management for metabolic comorbidities, and elderly patients need attention to polypharmacy and age-specific psychosocial supports. Finally, the setting in which care is delivered matters. Based on Treatment Setting, the market is studied across Inpatient and Outpatient environments, with inpatient care reserved for high-acuity stabilization while outpatient services form the backbone of long-term recovery and relapse prevention. Recognizing these segmentation layers enables stakeholders to align product design, reimbursement strategies, and clinical pathways to meet the needs of distinct user cohorts and care settings.

Regional insights comparing prevalence, care infrastructure, reimbursement, and innovation adoption that shape treatment access and service delivery

Regional dynamics exert strong influence on how binge eating disorder is identified, treated, and reimbursed, and they therefore shape strategic priorities for clinical programs and commercial planning. In the Americas, higher clinician awareness and expanding telehealth infrastructure support broader rollout of integrated care models, but regional heterogeneity in public and private payer policies means that reimbursement and access pathways vary significantly between jurisdictions. This drives a need for localized engagement with payers and health systems to demonstrate value through outcomes and cost-offset analyses.

In Europe, Middle East & Africa, regulatory frameworks and cultural context differ across countries, which affects adoption patterns. Some European markets have established behavioral health integration and national guidelines that facilitate standardized care pathways, while other jurisdictions within the Middle East and Africa are at earlier stages of diagnostic capacity and workforce development. These differences necessitate tailored approaches that consider local clinical training, stigma reduction, and infrastructure investments to expand access.

The Asia-Pacific region presents diverse opportunities and challenges due to variation in digital adoption, population demographics, and regulatory regimes. High mobile penetration in many Asia-Pacific markets supports rapid diffusion of mobile app-based interventions, yet language, cultural norms around eating behavior, and evolving reimbursement policies require careful localization of clinical content and engagement models. Across all regions, stakeholders benefit from region-specific evidence, partnerships with local clinical leaders, and capacity-building initiatives that reflect each region's unique epidemiology and healthcare delivery architecture.

Company-level insights on strategic positioning, collaborations, research priorities, and differentiation among treatment and digital therapy providers

Company strategies in the binge eating disorder landscape are defined by a mix of clinical innovation, strategic partnerships, and targeted commercialization models. Leading clinical developers and digital therapy providers are investing in rigorous outcome measurement, demonstrating efficacy through randomized studies and real-world evidence to support payer conversations. At the same time, alliances between technology providers and established behavioral health networks are enabling pilots that integrate digital tools into existing care pathways, reducing friction for clinician adoption and patient onboarding.

Pharmaceutical stakeholders pursuing pharmacologic options are focusing on differentiation through mechanism of action, tolerability, and evidence of sustained symptom reduction, while also considering the role of adjunctive use with psychotherapy. Specialty treatment centers and hospital systems are exploring value-based contracting arrangements tied to measurable recovery metrics, which encourages providers to report outcomes and iterate on care delivery models. New entrants are leveraging data science to refine patient segmentation and identify which interventions are most likely to succeed for particular patient profiles, creating opportunities for personalized care solutions.

Across the sector, the most successful organizations combine clinical credibility with distribution acumen, prioritizing interoperability, clinician engagement, and payer alignment. They also maintain flexible commercialization roadmaps that allow rapid local adaptation, accelerated partnership models, and investment in training programs to ensure fidelity to evidence-based interventions.

Actionable recommendations for leaders to accelerate adoption, strengthen care pathways, and align strategies with changing clinical and regulatory landscapes

Industry leaders should pursue a set of actionable initiatives that accelerate access to evidence-based care while protecting commercial viability. First, prioritize integrated care models that combine psychotherapeutic interventions with pharmacologic and digital options, and invest in longitudinal outcome measurement to demonstrate clinical and economic value. Second, develop interoperability and clinician-friendly workflows that make digital therapeutics a seamless component of routine care, thereby lowering adoption barriers and improving adherence.

Third, strengthen payer engagement by co-designing outcome frameworks and piloting value-based reimbursement models that reward sustained recovery rather than episodic service delivery. Fourth, insulate supply chains against policy shocks and trade disruptions through diversification, nearshoring where feasible, and transparent procurement strategies that account for potential tariff impacts. Fifth, invest in workforce capacity through clinician training programs focused on evidence-based psychotherapies and on integrating digital tools into therapeutic practice.

Finally, adopt an evidence-first commercialization strategy that sequences clinical validation, payer pilots, and provider partnerships to build credibility and scale. By aligning product development with clear clinical endpoints and payer needs, organizations can reduce commercial risk and accelerate uptake while maintaining ethical standards and patient-centered design principles.

Transparent methodology outlining data sources, analytical frameworks, validation steps, and quality controls to ensure rigorous and reproducible insights

The analysis underpinning this report uses a multi-source, evidence-driven methodology designed to maximize reliability and transparency. Primary inputs include peer-reviewed clinical literature, registry and trial databases, regulatory documents, and qualitative interviews with clinicians, payers, digital health innovators, and supply chain experts. These inputs were triangulated to reconcile differences in study design, patient populations, and outcome measures, and to assess the robustness of clinical effects across settings.

Quantitative findings were supplemented with qualitative insights from subject-matter experts and frontline providers to contextualize adoption barriers and implementation considerations. Data curation and synthesis followed a reproducible protocol: source provenance was recorded, analytical assumptions were documented, and internal replication checks were performed. Validation steps included cross-checking clinical effect estimates against trial registries, reviewing reimbursement pathways with payer consultants, and testing supply chain scenarios with procurement specialists to ensure scenario plausibility.

Limitations are acknowledged: evidence quality varies by intervention type, and some emerging modalities have limited long-term outcome data. To mitigate these constraints, the methodology emphasizes transparency and recommends ongoing evidence generation post-deployment. This approach supports decision-makers who require both rigor and practical guidance when planning clinical programs, commercial launches, or policy engagement.

Conclusive synthesis emphasizing strategic priorities, urgency of integrated care, and a clear pathway forward for stakeholders across clinical and policy domains

The landscape for binge eating disorder is characterized by both opportunity and complexity. Advances in digital therapeutics, renewed pharmacologic inquiry, and evolving care models collectively create avenues to improve access and outcomes, but realizing that potential requires coordinated action across clinical, commercial, and policy stakeholders. Integrated care pathways that bring together psychotherapy, pharmacotherapy, and digital supports are central to delivering sustained benefit and reducing relapse.

At the same time, external forces such as trade policy changes and regional differences in reimbursement and infrastructure introduce practical constraints that demand resilient supply chains, localized engagement strategies, and an evidence-driven approach to payer conversations. Organizations that invest in interoperability, real-world evidence generation, and clinician training will be better positioned to convert scientific advances into meaningful, scalable care.

In summary, the most effective path forward combines clinical rigor with operational resilience and stakeholder collaboration. By aligning investments with clear outcome metrics and by designing services that reflect the lived experience of patients across diverse settings and regions, stakeholders can advance both clinical and commercial goals while expanding equitable access to effective treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Binge Eating Disorder Market, by Treatment Type

  • 8.1. Digital Therapeutics
    • 8.1.1. Mobile App
    • 8.1.2. Web Based
  • 8.2. Pharmacotherapy
    • 8.2.1. Antidepressants
    • 8.2.2. Antiepileptics
    • 8.2.3. Stimulants
  • 8.3. Psychotherapy
    • 8.3.1. Cognitive Behavioral Therapy
    • 8.3.2. Dialectical Behavior Therapy
    • 8.3.3. Interpersonal Psychotherapy

9. Binge Eating Disorder Market, by Treatment Setting

  • 9.1. Inpatient
  • 9.2. Outpatient

10. Binge Eating Disorder Market, by Distribution Channel

  • 10.1. Home Healthcare
  • 10.2. Hospitals And Clinics
  • 10.3. Online Platforms
  • 10.4. Specialty Treatment Centers

11. Binge Eating Disorder Market, by End User

  • 11.1. Adolescents
  • 11.2. Adults
  • 11.3. Elderly

12. Binge Eating Disorder Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Binge Eating Disorder Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Binge Eating Disorder Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Binge Eating Disorder Market

16. China Binge Eating Disorder Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alsana, Inc.
  • 17.6. Amneal Pharmaceuticals, Inc.
  • 17.7. Apotex Inc. by SK Capital Partners LLP
  • 17.8. BALANCE Eating Disorder Treatment Center
  • 17.9. Carolina House Eating Disorder Treatment Center
  • 17.10. Center for Change
  • 17.11. Equip Health, Inc.
  • 17.12. Hikma Pharmaceuticals PLC
  • 17.13. Jazz Pharmaceuticals plc
  • 17.14. Johnson & Johnson Innovative Medicine by Johnson and Johnson
  • 17.15. Monte Nido & Affiliates Holdings, LLC
  • 17.16. Montecatini Eating Disorder Treatment Center
  • 17.17. Novo Nordisk A/S
  • 17.18. Pfizer Inc.
  • 17.19. Red Oak Recovery
  • 17.20. Rhodes Pharmaceuticals L.P. by Purdue Pharma L.P.
  • 17.21. SimSon Pharma Limited
  • 17.22. Sunovion Pharmaceuticals Inc. by Sumitomo Pharma
  • 17.23. Takeda Pharmaceutical Company Limited
  • 17.24. TalktoAngel
  • 17.25. The London Centre for Eating Disorders and Body Image Ltd.
  • 17.26. TheraCryf Plc
  • 17.27. Timberline Knolls Residential Treatment Center
  • 17.28. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BINGE EATING DISORDER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BINGE EATING DISORDER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GCC BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. G7 BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NATO BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. NATO BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)